Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Retrospective study of 472 NDMM pts treated with Dara-containing regimens at 10 EMN Italy centers finds 148 (31.3%) experienced infectious complications during therapy; earlier onset of infections in D-VTD group vs. others.”
Title: Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first-line regimens: A multicentric Italian experience
Authors: Angela Rago, Francesca Fioritoni, Carmine Liberatore, Stefano Pulini, Francesca Fazio, Maria Teresa Petrucci, Valerio De Stefano, Elena Rossi, Tommaso Za, Francesca Di Landro, Laura De Padua, Massimo Offidani, Sonia More, Annibali Ombretta, Valeria Tomarchio, Maria Antonietta Tafuri, Alfonso Piciocchi, Luca Franceschini, Alessia Fiorini. Tommaso Caravita di Toritto
You can read the Full Article in Annals of Hematology.
You can find more posts featuring Robert Orlowski on OncoDaily.
